Pulse Biosciences Inc
NASDAQ:PLSE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pulse Biosciences Inc
NASDAQ:PLSE
|
US |
|
Independent Bank Corp (Michigan)
NASDAQ:IBCP
|
US |
|
Arcticzymes Technologies ASA
OSE:AZT
|
NO |
|
National Health Investors Inc
NYSE:NHI
|
US |
|
Indra Sistemas SA
F:IDA
|
ES |
|
Sayona Mining Ltd
ASX:SYA
|
AU |
Pulse Biosciences Inc
Pulse Biosciences Inc. operates at the intriguing intersection of healthcare innovation and cutting-edge technology, focusing on the development and commercialization of their proprietary Nano-Pulse Stimulation (NPS) technology. NPS is a novel bio-electrical platform designed to deliver ultra-short electrical pulses designed to induce cell stress and modify cell structure without significantly impacting non-cellular structural elements. The company primarily concentrates on medical applications that demand precision and safety, notably in dermatology, oncology, and other critical therapeutic areas. By developing devices like the CellFX System, Pulse Biosciences allows physicians to treat conditions with minimal invasiveness, offering alternatives to traditional methods like surgery.
Pulse Biosciences generates revenue by selling these medical devices and fostering strategic partnerships within the healthcare sector to expand the application and adoption of NPS technology. The company's business model hinges on convincing healthcare professionals and institutions of the tangible benefits and potential cost savings that their innovative solutions offer. By aligning themselves with clinicians and medical researchers, Pulse Biosciences endeavors to expand the clinical indications for NPS technology, gradually scaling their market presence. Although the journey involves navigating the complex regulatory landscape and proof of clinical efficacy, the company aims to sustain growth through continuous innovation and market expansion, targeting widespread adoption of their groundbreaking platforms.
Pulse Biosciences Inc. operates at the intriguing intersection of healthcare innovation and cutting-edge technology, focusing on the development and commercialization of their proprietary Nano-Pulse Stimulation (NPS) technology. NPS is a novel bio-electrical platform designed to deliver ultra-short electrical pulses designed to induce cell stress and modify cell structure without significantly impacting non-cellular structural elements. The company primarily concentrates on medical applications that demand precision and safety, notably in dermatology, oncology, and other critical therapeutic areas. By developing devices like the CellFX System, Pulse Biosciences allows physicians to treat conditions with minimal invasiveness, offering alternatives to traditional methods like surgery.
Pulse Biosciences generates revenue by selling these medical devices and fostering strategic partnerships within the healthcare sector to expand the application and adoption of NPS technology. The company's business model hinges on convincing healthcare professionals and institutions of the tangible benefits and potential cost savings that their innovative solutions offer. By aligning themselves with clinicians and medical researchers, Pulse Biosciences endeavors to expand the clinical indications for NPS technology, gradually scaling their market presence. Although the journey involves navigating the complex regulatory landscape and proof of clinical efficacy, the company aims to sustain growth through continuous innovation and market expansion, targeting widespread adoption of their groundbreaking platforms.
Revenue Growth: Pulse Biosciences reported Q4 revenue of $264,000, up from $86,000 in Q3, driven by increased Vybrance system and disposable sales.
Clinical Progress: The company achieved key milestones, including IDE approvals for both electrophysiology catheter and cardiac surgical clamp programs, supporting pivotal trial enrollment in 2026.
Exceptional AFib Results: European feasibility studies for the nPulse cardiac catheter showed 96% procedural success at 1 year and 90% freedom from arrhythmia at 12 months, results that have drawn significant attention.
Vybrance Platform Launch: Vybrance for soft tissue ablation remains in limited release, with market expansion and broader commercialization to wait until more clinical data and reimbursement certainty are achieved.
Strong Balance Sheet: Pulse ended 2025 with $80.7 million in cash, supported by a new $200 million shelf registration for future financial flexibility.
Guidance & Outlook: Management is focused on executing pivotal trials, expanding European feasibility, progressing toward CE Mark submissions in 2026, and achieving FDA clearances in 2027.
Strategic Partnerships: The company is actively pursuing partnerships with mapping system providers to accelerate commercial launch and market entry for the nPulse system.
